Remove Hospital Remove Marketing Remove Safety
article thumbnail

INmune Bio to Submit FDA BLA for CORDStrom in RDEB

The Dermatology Digest

Food and Drug Administration (FDA) and Marketing Authorization Application (MAA) in the UK and EU for CORDStrom in Recessive Dystrophic Epidermolysis Bullosa (RDEB). This trial showed a favorable benefit-risk profile in support of the intended applications for marketing authorization. INmune Bio, Inc.

article thumbnail

Arch Amenities’ Catherine Warren on technology & creating memorable experiences.

Spa Executive

Offering a full spectrum of services, from design and brand development to recruiting, marketing, and day-to-day operations, Arch Amenities Group transforms key areas into activated, profitable spaces. We asked her about what she does, technology’s role in the hospitality and wellness space, and creating memorable experiences.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How to Avoid Cosmetic Procedure Scams

West Lake Dermatology

This comprehensive guide will help you recognize red flags, ask the right questions, and prioritize your safety. Board certified dermatologists , plastic surgeons, and licensed nurses or aestheticians adhere to stringent safety and ethical guidelines, ensuring optimal results and minimal risks.

Legal 36
article thumbnail

Galderma’s Nemolizumab Approved for AD and PN in the UK and Switzerland

The Dermatology Digest

Just days after snagging dual approvals for moderate-to-severe atopic dermatitis (AD) and prurigo nodularis (PN) in the European Union, nemolizumab (Nemluvio, Galderma) was also granted Marketing Authorization in the United Kingdom (UK) and Switzerland for AD and PN.

article thumbnail

EMA’s CHMP Recommends Krystal’s Vyjuvek for Dystrophic Epidermolysis Bullosa

The Dermatology Digest

approved by the EC, the Company expects to market B-VEC under the registered European trademark, Vyjuvek. The final EC decision is anticipated in the second quarter of 2025. The decision will be applicable to all European Union member states, as well as Iceland, Norway, and Liechtenstein.If

Therapy 36
article thumbnail

10 Best Nasal Sprays for COVID-19 (2023)

Aesthetics Advisor

Dr. Choudhury wrote: The group of patients used 1% PVP-I [One per cent Povidone Iodine Solution] have shown tremendously reduced mortality, morbidity and hospital as well as financial burden in this covid situation. The pharmacology, toxicity, and safety data for NO use in humans has been well-established for decades.

article thumbnail

From Mexico to Tanzania: emerging global wellness trends

Spa Executive

We asked a selection of top wellness and hospitality leaders around the world about what people are seeking out in their locales. The market for vibroacoustic spa beds has also expanded, leading to an anticipated increase in the integration of sound and vibration therapy into in-room spa and wellness treatments.